Radiation exposure, protection and risk from nuclear medicine procedures
KeywordsRadiation Protection Differentiate Thyroid Cancer Amifostine Peptide Receptor Radionuclide Therapy 131I Treatment
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
The authors are grateful to Ms Catherine Wrenn for her advice and skilful editorial support.
- 9.Ma C, Xie J, Jiang Z, Wang G, Zuo S. Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010. doi: 10.1007/s00259-009-1368-6.
- 10.Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging. 2009 Nov 14. [Epub ahead of print].Google Scholar
- 13.Asli IN, Baharfard N, Shafiei B, Tabei F, Javadi H, Seyedabadi M, et al. Relation between clinical and laboratory parameters with radiation dose rates from patients receiving iodine-131 therapy for thyroid carcinoma. Radiat Prot Dosimetry. 2009 Nov 17 [Epub ahead of print].Google Scholar
- 15.Watanabe H, Satou T, Senzui N, Kimura F, Sano M, Hoshi T, et al. National survey of radiation protection for workers in positron emission tomography facilities in Japan-1st report: occupational role assignment, radiation exposure to medical workers. Nippon Hoshasen Gijutsu Gakkai Zasshi. 2009;65(3):285–94.PubMedGoogle Scholar
© Springer-Verlag 2010